Mannkind: Overlooked Biotech With Excellent Prospects (Part V)

Part V: Mannkind’s (MNKD) pipeline potential 

This is part 5 of my six-part series covering Mannkind. In Part 1, I explained why Technosphere Insulin, Mannkind’s upcoming inhaled insulin, is a breakthrough product with the potential to significantly improve diabetes treatment. In Part 2, I explained why Pfizer’s (PFE) lung cancer scare with Exubera (a competing inhaled insulin) was just that – a scare. In Part 3, I highlighted some of the differences between Pfizer’s failed Exubera and Mannkind’s Technosphere Insulin. In Part 4, I discussed Mannkind’s partnership opportunities and options for Technosphere Insulin.